Sun Governance Efforts, Ilumya US Run In Focus Ahead Of Q4
Executive Summary
Ahead of its Q4 earnings, Sun Pharma has indicated its intent to take additional steps to address investor unease and perceptions around gaps in corporate governance. Investors are expected to keep a close watch on the company's efforts in these areas as well as on management commentary around the US uptake of psoriasis asset Ilumya.
You may also be interested in...
Sun US Chief Settles Insider Trading Case
Top Sun Pharma executive Abhay Gandhi and his wife have settled a case pertaining to alleged insider trading in shares of Ranbaxy around the time of the company’s acquisition by Sun from Daiichi Sankyo in 2014. Sun, which has been firefighting a raft of governance concerns, has vouched for the executive’s integrity.
Sun’s Ilumya Gnaws At US Psoriasis Market
Around 800 physicians have prescribed Sun’s Ilumya, giving it some early traction in the competitive US psoriasis market. The Indian firm is striving to push harder and will also take a call on pursuing additional indications for the product.
Sun Firefights Governance Concerns
Sun has promised to implement certain changes to address corporate governance concerns that have riled investors, including “unwinding” a loan transaction and doing away with a controversial related party arrangement for domestic sales. But will that be enough for markets to "forget" allegations of lapses or "re-rate" the firm any time soon?